Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

Detalles Bibliográficos
Autores principales: Brandão, Mariana, Reyal, Fabien, Hamy, Anne-Sophie, Piccart-Gebhart, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555612/
https://www.ncbi.nlm.nih.gov/pubmed/31231570
http://dx.doi.org/10.1136/esmoopen-2019-000515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555612/
https://www.ncbi.nlm.nih.gov/pubmed/31231570
http://dx.doi.org/10.1136/esmoopen-2019-000515

Ejemplares similares